Id: acc4895
Group: 2sens
Protein: FRS2
Gene Symbol: FRS2
Protein Id: Q8WU20
Protein Name: FRS2_HUMAN
PTM: phosphorylation
Site: Thr
Site Sequence:
Disease Category: Nervous system diseases
Disease: Neuronal Differentiation
Disease Subtype: EGFinduced
Disease Cellline: PC-12
Disease Info:
Drug: POV
Drug Info: "The information is insufficient to accurately describe the drug ""POV"" in a formal and academic way. "
Effect: modulate
Effect Info: "The phosphatase pan - inhibitor POV can simultaneously induce the phosphorylation of threonine and tyrosine in FRS2, indicating that it may enhance various phosphorylation modifications by inhibiting phosphatase activity."
Note: no disease
Score: 2.0
Pubmed(PMID): 19652666
Sentence Index:
Sentence:

Sequence & Structure:

MGSCCSCPDKDTVPDNHRNKFKVINVDDDGNELGSGIMELTDTELILYTRKRDSVKWHYLCLRRYGYDSNLFSFESGRRCQTGQGIFAFKCARAEELFNMLQEIMQNNSINVVEEPVVERNNHQTELEVPRTPRTPTTPGFAAQNLPNGYPRYPSFGDASSHPSSRHPSVGSARLPSVGEESTHPLLVAEEQVHTYVNTTGVQEERKNRTSVHVPLEARVSNAESSTPKEEPSSIEDRDPQILLEPEGVKFVLGPTPVQKQLMEKEKLEQLGRDQVSGSGANNTEWDTGYDSDERRDAPSVNKLVYENINGLSIPSASGVRRGRLTSTSTSDTQNINNSAQRRTALLNYENLPSLPPVWEARKLSRDEDDNLGPKTPSLNGYHNNLDPMHNYVNTENVTVPASAHKIEYSRRRDCTPTVFNFDIRRPSLEHRQLNYIQVDLEGGSDSDNPQTPKTPTTPLPQTPTRRTELYAVIDIERTAAMSNLQKALPRDDGTSRKTRHNSTDLPM

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
Q8WU20 FRS2 P Ser221;Thr227 VS(ph)NAESST(ph)PKEEPSSIEDRDPQILLEPEGVK A549 Dactolisib 6.3961 up
Q8WU20 FRS2 P Thr227 VSNAESST(ph)PKEEPSSIEDRDPQILLEPEGVK A549 Refametinib 8.5715 down
Q8WU20 FRS2 P Thr227 VSNAESST(ph)PKEEPSSIEDRDPQILLEPEGVK A549 PD325901 9.1765 down
Q8WU20 FRS2 P Thr227 VSNAESST(ph)PKEEPSSIEDRDPQILLEPEGVK A549 PD325901 9.3754 down
Q8WU20 FRS2 P Thr210 NRT(ph)SVHVPLEAR A549 MK2206 4.8877 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 Tideglusib 5.7609 -
Q8WU20 FRS2 P Thr210 KNRT(ph)SVHVPLEAR A549 Tideglusib 8.7626 -
Q8WU20 FRS2 P Ser226;Thr227 VSNAESS(ph)T(ph)PKEEPSSIEDRDPQILLEPEGVK A549 Refametinib 7.8874 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 Refametinib 11.1077 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 Pictilisib 10.7523 -
Q8WU20 FRS2 P Thr465 TPTTPLPQTPT(ph)RR A549 PD325901 5.759 -
Q8WU20 FRS2 P Thr210 NRT(ph)SVHVPLEAR A549 PD325901 6.8786 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 PD325901 8.7473 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 PD325901 9.9258 -
Q8WU20 FRS2 P Ser221;Thr227 VS(ph)NAESST(ph)PKEEPSSIEDRDPQILLEPEGVK A549 PD325901 10.6601 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 Nintedanib 10.3953 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A431 Dasatinib 7.7245 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 MK2206 8.9499 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 Dasatinib 5.2229 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 Dasatinib 5.2475 -
Q8WU20 FRS2 P Thr210 NRT(ph)SVHVPLEAR A549 Dasatinib 6.6567 -
Q8WU20 FRS2 P Thr227 VSNAESST(ph)PKEEPSSIEDRDPQILLEPEGVK A549 Dasatinib 6.9503 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A549 Dactolisib 6.3066 -
Q8WU20 FRS2 P Thr210 KNRT(ph)SVHVPLEAR A549 Dactolisib 7.6283 -
Q8WU20 FRS2 P Thr210 KNRT(ph)SVHVPLEAR A549 AZD8055 6.7439 -
Q8WU20 FRS2 P Thr504 HNST(ph)DLPM A431 Gefitinib 6.1421 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A431 Gefitinib 6.5021 -
Q8WU20 FRS2 P Thr210 T(ph)SVHVPLEAR A431 Gefitinib 5.6814 -
Q8WU20 FRS2 P Ser226;Thr227;Ser233 VSNAESS(ph)T(ph)PKEEPS(ph)SIEDRDPQILLEPEGVK A431 Dasatinib 16.5229 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: